AR098048A1 - Inhibidores de fgfr4 - Google Patents
Inhibidores de fgfr4Info
- Publication number
- AR098048A1 AR098048A1 ARP140103845A ARP140103845A AR098048A1 AR 098048 A1 AR098048 A1 AR 098048A1 AR P140103845 A ARP140103845 A AR P140103845A AR P140103845 A ARP140103845 A AR P140103845A AR 098048 A1 AR098048 A1 AR 098048A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- alkoxy
- hydrogen
- nr5r6
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se proporcionan compuestos útiles como inhibidores de FGFR4, así como sus métodos de uso. FGFR4 definido como Receptor del Factor de Crecimiento de Fibroblastos 4. Reivindicación 1: Un compuesto de fórmula (1), en donde: R³ se selecciona del grupo que consta de: alquilo C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, NR¹⁰R¹¹-alquilo C₁₋₆, heterociclilo-R¹⁰-alquilo C₁₋₆, arilo-R¹⁰-alquilo C₁₋₆, y heteroarilo-R¹⁰-alquilo C₁₋₆, en donde R¹⁰ y R¹¹ cada uno se selecciona de modo independiente del grupo que consta de: hidrógeno y alquilo C₁₋₆; E se selecciona del grupo que consta de: -NR¹³C(O)CR¹⁴=CHR¹⁵, y -NR¹³C(O)CºCR¹⁴, en donde R¹³ se selecciona del grupo que consta de: hidrógeno y metilo, y R¹⁴ y R¹⁵ cada uno se selecciona de modo independiente del grupo que consta de: hidrógeno, metilo, flúor y cloro; R¹² se selecciona del grupo que consta de: hidrógeno, halo, alquilo C₁₋₆, alcoxi C₁₋₆, hidroxialquilo C₁₋₆, hidroxialcoxi C₁₋₆, alcoxi C₁₋₆-alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, heterociclilo-R⁵R⁶, -C(O)heterociclilo-R⁵R⁶, R⁵R⁶-heterociclilo-alquilo C₁₋₆, NR⁵R⁶, NR⁵R⁶-alquilo C₁₋₆, -C(O)NR⁵R⁶, y NR⁵R⁶-alquiloxi C₁₋₆, en donde R⁵ y R⁶ cada uno se selecciona de modo independiente del grupo que consta de hidrógeno, alquilo C₁₋₆, hidroxialquilo C₁₋₆, aminoalquilo C₁₋₆, -C(O)alquilo C₁₋₆ y alquilo C₁₋₆sulfonilo; y R¹ es fenilo, en donde dicho fenilo está sustituido 2, 3, ó 4 veces con halo o alcoxi C₁₋₆ independientemente seleccionados; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892881P | 2013-10-18 | 2013-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098048A1 true AR098048A1 (es) | 2016-04-27 |
Family
ID=51842899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103845A AR098048A1 (es) | 2013-10-18 | 2014-10-16 | Inhibidores de fgfr4 |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9434697B2 (es) |
| EP (2) | EP3421457B1 (es) |
| JP (2) | JP6139788B2 (es) |
| KR (1) | KR101826015B1 (es) |
| CN (2) | CN110354128A (es) |
| AR (1) | AR098048A1 (es) |
| AU (2) | AU2014337291B9 (es) |
| BR (1) | BR112016008110B1 (es) |
| CA (1) | CA2924206C (es) |
| CL (1) | CL2016000918A1 (es) |
| CY (1) | CY1121129T1 (es) |
| DK (1) | DK3057943T3 (es) |
| ES (1) | ES2679521T3 (es) |
| HK (1) | HK1223091A1 (es) |
| HR (1) | HRP20181129T1 (es) |
| HU (1) | HUE039268T2 (es) |
| IL (1) | IL244373B (es) |
| JO (1) | JO3515B1 (es) |
| LT (1) | LT3057943T (es) |
| MX (1) | MX2016004933A (es) |
| MY (1) | MY184733A (es) |
| NZ (1) | NZ717559A (es) |
| PE (1) | PE20160679A1 (es) |
| PH (1) | PH12016500676A1 (es) |
| PL (1) | PL3057943T3 (es) |
| PT (1) | PT3057943T (es) |
| RS (1) | RS57444B1 (es) |
| RU (1) | RU2715708C2 (es) |
| SG (1) | SG11201602069WA (es) |
| SI (1) | SI3057943T1 (es) |
| TW (1) | TWI597268B (es) |
| UA (1) | UA116920C2 (es) |
| WO (2) | WO2015057963A1 (es) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| SG10201610416TA (en) | 2012-06-13 | 2017-01-27 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
| PT2872491T (pt) | 2012-07-11 | 2021-08-05 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| UA120248C2 (uk) | 2013-03-15 | 2019-11-11 | Селджен Кар Ллс | Гетероарильні сполуки та їх застосування |
| AR095464A1 (es) | 2013-03-15 | 2015-10-21 | Celgene Avilomics Res Inc | Compuestos de heteroarilo y usos de los mismos |
| KR102219695B1 (ko) | 2013-03-15 | 2021-02-25 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
| RU2715708C2 (ru) | 2013-10-18 | 2020-03-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Ингибиторы fgfr4 |
| EA028819B1 (ru) | 2013-10-25 | 2018-01-31 | Новартис Аг | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 |
| JP6458023B2 (ja) | 2013-10-25 | 2019-01-23 | ブループリント メディシンズ コーポレイション | 繊維芽細胞成長因子受容体の阻害剤 |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MX2020004108A (es) | 2015-02-20 | 2022-01-03 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| SG10201810057UA (en) * | 2015-04-14 | 2018-12-28 | Eisai R&D Man Co Ltd | Crystalline fgfr4 inhibitor compound and uses thereof |
| WO2017015363A1 (en) * | 2015-07-20 | 2017-01-26 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| US10624897B2 (en) | 2015-07-20 | 2020-04-21 | Taipei Medical University | Chlorobenzene substituted azaaryl compounds |
| CN105418441A (zh) * | 2015-12-22 | 2016-03-23 | 中国工程物理研究院化工材料研究所 | 2,3-二氯-4-羟基苯胺的制备方法 |
| US10934311B2 (en) | 2016-01-08 | 2021-03-02 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound used as FGFR inhibitor |
| JP7372740B2 (ja) * | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
| CN107400092B (zh) * | 2016-05-20 | 2021-08-24 | 浙江海正药业股份有限公司 | 嘧啶类衍生物及其制备方法和其在医药上的用途 |
| WO2017198221A1 (zh) | 2016-05-20 | 2017-11-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| CN105884760B (zh) * | 2016-06-13 | 2019-01-04 | 厦门市蔚嘉化学科技有限公司 | 一种可比司他中间体的制备方法 |
| JP7190425B2 (ja) * | 2016-08-23 | 2022-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌の治療のための併用療法 |
| US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| CN109922804B (zh) | 2016-11-02 | 2023-11-17 | 诺华股份有限公司 | Fgfr4抑制剂和胆汁酸螯合剂的组合 |
| NZ754218A (en) | 2016-11-17 | 2021-07-30 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Fgfr4 inhibitor and preparation method and use thereof |
| KR101812266B1 (ko) | 2016-11-25 | 2017-12-27 | 한국과학기술연구원 | 4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용 |
| CN108239069B (zh) * | 2016-12-26 | 2021-01-05 | 南京药捷安康生物科技有限公司 | 一种用于成纤维细胞生长因子受体的抑制剂及其用途 |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN110691775B (zh) * | 2017-08-04 | 2021-04-23 | 上海和誉生物医药科技有限公司 | 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用 |
| CN109422760B (zh) * | 2017-09-01 | 2022-05-27 | 南京圣和药物研发有限公司 | Fgfr4抑制剂及其应用 |
| EP3680236A4 (en) | 2017-09-05 | 2021-04-21 | Bioardis LLC | AROMATIC DERIVATIVE, MANUFACTURING PROCESS FOR IT AND MEDICAL APPLICATION OF IT |
| BR112020014112A2 (pt) | 2018-01-10 | 2020-12-01 | Eisai R&D Management Co., Ltd. | terapias de combinação para o tratamento de carcinoma hepatocelular |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| WO2019242689A1 (zh) * | 2018-06-22 | 2019-12-26 | 北京赛特明强医药科技有限公司 | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 |
| WO2020177067A1 (en) | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| TW202108574A (zh) | 2019-05-10 | 2021-03-01 | 美商迪賽孚爾製藥有限公司 | 雜芳基胺基嘧啶醯胺自噬抑制劑及其使用方法 |
| WO2020257180A1 (en) | 2019-06-17 | 2020-12-24 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112341344B (zh) * | 2019-08-09 | 2021-10-26 | 上海喀露蓝科技有限公司 | 一种激酶抑制剂中间体的制备方法 |
| IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN113087671B (zh) * | 2019-12-23 | 2022-10-21 | 北京赛特明强医药科技有限公司 | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 |
| US20230172867A1 (en) | 2020-05-15 | 2023-06-08 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor |
| JP2023533903A (ja) | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
| JPWO2022075482A1 (es) | 2020-10-05 | 2022-04-14 | ||
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CN115490670A (zh) * | 2021-06-17 | 2022-12-20 | 浙江海正药业股份有限公司 | Fgfr4选择性抑制剂的盐及其制备方法和用途 |
| CN115504965A (zh) | 2021-06-23 | 2022-12-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物的晶型及其制备方法 |
| CN114276266A (zh) * | 2021-12-30 | 2022-04-05 | 兰州康鹏威耳化工有限公司 | 一种4-氨基-2-氟苯甲酰胺的制备方法 |
| CN114560815A (zh) * | 2022-03-04 | 2022-05-31 | 北京工业大学 | (2-((5-氯-取代苯基氨基嘧啶-2-基)氨基)苯基)氨基甲酸叔丁酯类衍生物 |
| CN114835640B (zh) * | 2022-05-24 | 2024-02-13 | 中国药科大学 | 成纤维细胞生长因子受体抑制剂、制备方法及应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2054867T3 (es) * | 1987-09-28 | 1994-08-16 | Ciba Geigy Ag | Plaguicidas y pesticidas. |
| EP1080092B1 (en) | 1998-05-26 | 2008-07-23 | Warner-Lambert Company LLC | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| CA2533774A1 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| GEP20105074B (en) | 2005-12-21 | 2010-09-10 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| CA2702647C (en) * | 2007-01-31 | 2016-03-22 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| US20090062320A1 (en) | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
| KR101892989B1 (ko) | 2008-06-27 | 2018-08-30 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| KR20120130758A (ko) | 2010-01-14 | 2012-12-03 | 예일 유니버시티 | 수용체 티로신 키나제 (ｒｔｋ)의 억제제 및 그의 사용 방법 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012136732A1 (en) | 2011-04-08 | 2012-10-11 | Ab Science | Treatment of multiple myeloma with masitinib |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| CN104168920A (zh) | 2012-01-18 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 使用fgf19调控剂的方法 |
| US9464077B2 (en) | 2012-02-28 | 2016-10-11 | Astellas Pharma Inc. | Nitrogen-containing aromatic heterocyclic compound |
| PT2872491T (pt) * | 2012-07-11 | 2021-08-05 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| EP2968339A4 (en) * | 2013-03-15 | 2017-02-15 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| KR102219695B1 (ko) * | 2013-03-15 | 2021-02-25 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| WO2015006492A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| AR097455A1 (es) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
| RU2715708C2 (ru) * | 2013-10-18 | 2020-03-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Ингибиторы fgfr4 |
| JP6458023B2 (ja) | 2013-10-25 | 2019-01-23 | ブループリント メディシンズ コーポレイション | 繊維芽細胞成長因子受容体の阻害剤 |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| CN109071532B (zh) | 2016-05-20 | 2021-04-27 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
| WO2017198221A1 (zh) | 2016-05-20 | 2017-11-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
-
2014
- 2014-10-16 RU RU2016118981A patent/RU2715708C2/ru active
- 2014-10-16 AU AU2014337291A patent/AU2014337291B9/en active Active
- 2014-10-16 CN CN201910565163.7A patent/CN110354128A/zh active Pending
- 2014-10-16 WO PCT/US2014/060902 patent/WO2015057963A1/en active Application Filing
- 2014-10-16 BR BR112016008110-2A patent/BR112016008110B1/pt active IP Right Grant
- 2014-10-16 SI SI201430792T patent/SI3057943T1/en unknown
- 2014-10-16 CA CA2924206A patent/CA2924206C/en active Active
- 2014-10-16 MY MYPI2016000489A patent/MY184733A/en unknown
- 2014-10-16 UA UAA201605322A patent/UA116920C2/uk unknown
- 2014-10-16 ES ES14790956.8T patent/ES2679521T3/es active Active
- 2014-10-16 HU HUE14790956A patent/HUE039268T2/hu unknown
- 2014-10-16 AR ARP140103845A patent/AR098048A1/es unknown
- 2014-10-16 CN CN201480056358.4A patent/CN105899490B/zh active Active
- 2014-10-16 JP JP2016523266A patent/JP6139788B2/ja active Active
- 2014-10-16 EP EP18167989.5A patent/EP3421457B1/en active Active
- 2014-10-16 NZ NZ717559A patent/NZ717559A/en unknown
- 2014-10-16 PE PE2016000460A patent/PE20160679A1/es unknown
- 2014-10-16 PL PL14790956T patent/PL3057943T3/pl unknown
- 2014-10-16 EP EP14790956.8A patent/EP3057943B1/en active Active
- 2014-10-16 PT PT147909568T patent/PT3057943T/pt unknown
- 2014-10-16 DK DK14790956.8T patent/DK3057943T3/en active
- 2014-10-16 RS RS20180834A patent/RS57444B1/sr unknown
- 2014-10-16 MX MX2016004933A patent/MX2016004933A/es unknown
- 2014-10-16 TW TW103135880A patent/TWI597268B/zh active
- 2014-10-16 WO PCT/US2014/060857 patent/WO2015057938A1/en active Application Filing
- 2014-10-16 SG SG11201602069WA patent/SG11201602069WA/en unknown
- 2014-10-16 KR KR1020167009625A patent/KR101826015B1/ko active IP Right Grant
- 2014-10-16 JO JOP/2014/0297A patent/JO3515B1/ar active
- 2014-10-16 LT LTEP14790956.8T patent/LT3057943T/lt unknown
-
2016
- 2016-01-19 US US15/000,659 patent/US9434697B2/en active Active
- 2016-03-01 IL IL244373A patent/IL244373B/en active IP Right Grant
- 2016-04-12 PH PH12016500676A patent/PH12016500676A1/en unknown
- 2016-04-18 CL CL2016000918A patent/CL2016000918A1/es unknown
- 2016-07-27 US US15/221,018 patent/US9730931B2/en active Active
- 2016-09-23 HK HK16111183.6A patent/HK1223091A1/zh unknown
-
2017
- 2017-04-27 JP JP2017088732A patent/JP2017160233A/ja active Pending
- 2017-06-20 US US15/627,851 patent/US10537571B2/en active Active
-
2018
- 2018-07-17 HR HRP20181129TT patent/HRP20181129T1/hr unknown
- 2018-07-18 CY CY181100754T patent/CY1121129T1/el unknown
- 2018-11-27 AU AU2018271284A patent/AU2018271284B2/en active Active
-
2019
- 2019-12-17 US US16/717,080 patent/US10912774B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098048A1 (es) | Inhibidores de fgfr4 | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| UY35643A (es) | Nuevos compuestos útiles como nematicidas, sus composiciones y métodos de uso | |
| MX362582B (es) | Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. | |
| PE20151448A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| AR095347A1 (es) | Compuestos orgánicos | |
| CR20140216A (es) | 5,7-imidazo[1,2-c]pirimidinas sustituidas | |
| AR097543A1 (es) | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| CR20160171A (es) | NUEVO OCTAHIDRO-CICLOBUTA[1,2-c; 3,4-c] DIPIRROL-2-ILO | |
| ECSP11011258A (es) | Pirimidinas fusionadas | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| UY35626A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR092288A1 (es) | Ligandos del receptor ep1 |